Plasma midkine level is a prognostic factor for human neuroblastoma

Cancer Science

Volumn 99, Issue 10, 2008, Pages 2070-2074

  Ikematsu, Shinya ^a   Nakagawara, Akira ^b   Nakamura, Yohko ^b   Ohira, Miki ^b   Shinjo, Masaki ^c   Kishida, Satoshi ^d   Kadomatsu, Kenji ^d  

^a OKINAWA NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^b Chiba Institute of Science   (Japan)

^c Okinawa Prefectural College of Nursing   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MIDKINE; ONCOPROTEIN; PROTEIN MYCN; PROTEIN TYROSINE KINASE A; UNCLASSIFIED DRUG;

AGE; ARTICLE; BLOOD SAMPLING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MASS SCREENING; NEUROBLASTOMA; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

CASE-CONTROL STUDIES; CYTOKINES; HUMANS; MASS SCREENING; NEUROBLASTOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 54949085425     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00957.x     Document Type: Article

References (23)

1. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-16.
2. Henry MC, Tashjian DB, Breuer CK. Neuroblastoma update. Curr Opin Oncol 2005; 17: 19-23.
3. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commum 1988; 151: 1312-18.
4. Tomomura M, Kadomatsu K, Nakamoto M et al. A retinoic acid responsive gene, MK, produces a secreted protein with heparin binding activity. Biochem Biophys Res Commum 1990; 171: 603-9.
5. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204: 127-43.
6. Tsutsui J, Kadomatsu K, Matsubara S et al. A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281-5.
7. Aridome K, Tsutsui J, Takao S et al. Increased midkine gene expression in human gastrointestinal cancers. Jpn J Cancer Res 1995; 86: 655-61.
8. Mishima K, Asai A, Kadomatsu K et al. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997; 233: 29-32.
9. O'Brien T, Cranston D, Fuggle S et al. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56: 2515-18.
10. Garver RI Jr, Radford DM, Donis-Keller H et al. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584-90.
11. Ye C, Qi M, Fan QW et al. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999; 79: 179-84.
12. Konishi N, Nakamura M, Nakaoka S et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57: 253-7.
13. Takei Y, Kadomatsu K, Matsuo S et al. Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells. Cancer Res 2001; 61: 8486-91.
14. Takei Y, Kadomatsu K, Itoh H et al. 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy. J Biol Chem 2002; 277: 23.800-6.
15. Ikematsu S, Nakagawara A, Nakamura Y et al. Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas. Br J Cancer 2003; 88: 1522-6.
16. Ikematsu S, Yano A, Aridome K et al. Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000; 83: 701-6.
17. Ohira M, Oba S, Nakamura Y et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337-50.
18. Warnat P, Oberthuer A, Fischer M et al. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer 2007; 7: 89-99.
19. Joshi VV, Cantor AB, Brodeur GM et al. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer 1993; 71: 3173-81.
20. Hann HW, Levy HM, Evans AE. Serum ferritin as a guide to therapy in neuroblastoma. Cancer Res 1980; 40: 1411-3.
21. Zeltzer PM, Marangos PJ, Parma AM et al. Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group. Lancet 1983; 2: 361-3.
22. Valentino L, Moss T, Olson E et al. Shed tumor gangliosides and progression of human neuroblastoma. Blood 1990; 75: 1564-7.
23. Okabe-Kado J, Kasukabe T, Honma Y et al. Clinical significance of serum NM23-H1 protein in neuroblastoma. Cancer Sci 2005; 96: 653-60.